-
41.发明授权
公开(公告)号：KR101561610B1
公开(公告)日：2015-10-22
申请号：KR1020130146061
申请日：2013-11-28
Applicant: 한국화학연구원
Abstract: 본발명은본 발명은난용성약물이봉입된리포좀나노입자를포함하는장기안정성이우수한약학적제제및 이의제조방법에관한것으로써,본발명에따른난용성약물이봉입된리포좀나노입자크기는 30-900 nm로이를포함하는약학적제제의용해도를향상시키고, 장기안정성이우수하므로, 약물의생체이용률을향상시킬수 있다. 또한, 상기약학적제제는용이한제조방법으로제조할수 있으므로안정성이필요한난용성약물에유용하게적용할수 있다.
-
公开(公告)号：KR1020090128918A
公开(公告)日：2009-12-16
申请号：KR1020080054901
申请日：2008-06-11
Applicant: 한국화학연구원
IPC: A61K9/22 , A61K9/52 , A61K31/505
CPC classification number: A61K9/2866 , A61K9/2813 , A61K9/282 , A61K9/286 , A61K31/517 , A61K33/20 , A61K2300/00
Abstract: PURPOSE: A sustained release containing alfuzosin HCl is provided to control drug release rate through control of kind and thickness of material and improve sustained release property. CONSTITUTION: A sustained release formulation containing alfuzosin comprises crystal core; a pharmacologically active ingredient layer containing alfuzosin HCl, water-insoluble polymer, water-soluble polymer or their mixture; a sustained release layer containing a sustained release film forming material; and a pharmaceutically active ingredient layer containing alfuzosin HCl and water-insoluble polymer, water-soluble polymer or their mixture.
Abstract translation: 目的：提供含有盐酸阿夫唑嗪的持续释放，以通过控制材料的种类和厚度来控制药物释放速率，并提高持续释放性能。 构成：含有阿夫唑嗪的缓释制剂包括晶核; 含有盐酸阿夫唑嗪，水不溶性聚合物，水溶性聚合物或其混合物的药理活性成分层; 含有缓释膜形成材料的持续释放层; 以及含有盐酸阿夫唑嗪和水不溶性聚合物，水溶性聚合物或其混合物的药物活性成分层。
-
公开(公告)号：KR1020080058041A
公开(公告)日：2008-06-25
申请号：KR1020060132082
申请日：2006-12-21
Applicant: 한국화학연구원
CPC classification number: A61K9/0002 , A61K9/1635 , A61K9/1652 , A61K9/167 , A61K9/1688 , A61K31/404
Abstract: A controlled release pellet including indapamide is provided to control release of a drug more delicately than a tablet including the indapamide and increase compliance of a patient by being able to be administered one time per day. A controlled release pellet including indapamide comprises: a crystalline core(A); a pharmacologically active ingredient layer(B) formed on the surface of the crystalline core and including a drug containing the indapamide and a binder consisting of a water-insoluble polymer and a water-soluble polymer; and a release layer(C) formed on the surface of the pharmacologically active ingredient layer and including a release-type film forming material. The pellet comprises at least one lipophilic material coating layer between the pharmacologically active ingredient layer and the release layer.
Abstract translation: 提供包含吲达帕胺的控释丸，以控制药物比包括吲达帕胺在内的片剂更精细的释放，并且通过每天可以一次给药来增加患者的依从性。 包含吲达帕胺的控释丸包括：晶核（A）; 在结晶核心的表面上形成药物活性成分层（B），并且包含含有吲达帕胺的药物和由不溶于水的聚合物和水溶性聚合物组成的粘合剂; 以及形成在药理活性成分层的表面上并具有剥离型成膜材料的剥离层（C）。 颗粒包含药理活性成分层和释放层之间的至少一个亲脂性材料包衣层。
-
公开(公告)号：KR100774613B1
公开(公告)日：2007-11-12
申请号：KR1020060047682
申请日：2006-05-26
Applicant: 한국화학연구원
CPC classification number: A61K9/5078 , A61K31/00 , A61K31/445 , A61K31/517
Abstract: A sustained release drug delivery system is provided to reduce viscosity and increase sustained release property of a drug by using at least one water insoluble polymer together, thereby improving uniformity of particles and sustained drug release property of the system. A sustained release drug delivery system contains: a crystalline core material(A); 1-45 wt.% of a water insoluble polymer selected from ethylcellulose, cellulose acetate, polymethylmetacrylate copolymer, polyvinyl acetate and acetate-polyvinyl pyrrolidone copolymer and formed on the outer surface of the crystalline core material; an active component layer(B) containing a pharmaceutically active component selected from venlafaxine, prazosin, doxazosin HCl, methylphenidate, verapamil, oxybutynin chloride, isradipine, glipizide, pseudoephedrine HCl, albuterol sulfate, bupropion and paroxetine and formed on the outer surface of the water insoluble polymer layer; and a sustained release layer(C) containing a sustained release membrane-forming material and formed on the outer surface of the active component layer.
Abstract translation: 提供缓释药物递送系统以通过使用至少一种不溶于水的聚合物一起降低药物的粘度和增加持续释放性能，从而改善粒子的均匀性和持续的药物释放性质。 缓释药物递送系统包含：晶体芯材料（A）; 1-45重量％的选自乙基纤维素，乙酸纤维素，聚甲基丙烯酸甲酯共聚物，聚乙酸乙烯酯和乙酸酯 - 聚乙烯吡咯烷酮共聚物的水不溶性聚合物，并形成在结晶芯材的外表面上; 活性成分层（B），其含有药物活性成分，其选自文拉法辛，哌唑嗪，盐酸多沙唑嗪，哌甲酯，维拉帕米，氯化奥昔布宁，伊拉地平，格列吡嗪，盐酸假麻黄碱，硫酸沙丁胺醇，安非他酮和帕罗西汀，并形成在水的外表面 不溶性聚合物层; 和含有缓释膜形成材料的缓释层（C），形成在活性成分层的外表面上。
-
公开(公告)号：KR100426346B1
公开(公告)日：2004-04-08
申请号：KR1020000072016
申请日：2000-11-30
Applicant: 한국화학연구원
Abstract: PURPOSE: A pharmaceutical compositions for hypercholesterolemia treatment using of self microemulsifying drug delivery system is provided, thereby improving the solubility and bioavailability of a drug hardly dissolved. CONSTITUTION: The pharmaceutical composition useful for hyperlipidemia treatment using a self microemulsifying drug delivery system(SMEDDS) comprises 1 to 20 wt.% of statin, 5 to 60 wt.% of surfactant, 10 to 60 wt.% of solubilizing agent and 10 to 60 wt.% of co-surfactant, wherein the statin is lovastatin or simvastatin; the surfactant is selected from caster oils, substituted caster oils, twins, spans and bridge; the solubilizing agent is selected from fatty acid ester consisting of propyleneglycol monocaprylate, polyglycolide of oleic acid and linoleic acid, propyleneglycol monolaurate and polyglyceryl dioleate, vegetable oils consisting of coconut oil, olive oil, corn oil, caster oil, macadamia nut oil, apricot oil and unsaturated fatty acid, purified oil, and hydrophobic solubilizing agent; and the co-surfactant is selected from polyethyleneglycol, propylene glycol, dimethylisosorbid and diethyleneglycolmonoethylether.
Abstract translation: 目的：提供一种使用自微乳化药物递送系统治疗高胆固醇血症的药物组合物，由此提高几乎不溶解的药物的溶解度和生物利用度。 组成：用于使用自微乳化药物递送系统（SMEDDS）进行高脂血症治疗的药物组合物包含1至20重量％的他汀，5至60重量％的表面活性剂，10至60重量％的增溶剂和10至 60重量％的辅助表面活性剂，其中他汀为洛伐他汀或辛伐他汀; 表面活性剂选自蓖麻油，取代的蓖麻油，双胞胎，跨度和桥; 增溶剂选自由丙二醇单辛酸酯，油酸和亚油酸的聚乙交酯，丙二醇单月桂酸酯和聚甘油二油酸酯组成的脂肪酸酯，由椰子油，橄榄油，玉米油，蓖麻油，澳大利亚坚果油，杏仁油 和不饱和脂肪酸，精制油和疏水增溶剂; 辅助表面活性剂选自聚乙二醇，丙二醇，二甲基异山梨醇和二甘醇单乙基醚。
-
Patent Agency Ranking
公开(公告)号：KR100342388B1
公开(公告)日：2002-07-04
申请号：KR1019990048381
申请日：1999-11-03
Applicant: 한국화학연구원
IPC: A61K9/70
Abstract: 본발명은경피투여용약물전달시스템에관한것으로서, 이약물전달시스템은유효성분으로케토롤락또는약리학적으로사용가능한그의염을포함하고점착제및 피부투과촉진제를포함하는약물함유점착제층, 상기점착제층아래에형성되어있고, 폴리이소부틸렌을포함하며상기케토롤락을피부로이행시키기위한피부이행층및 상기점착제층과피부이행층을지지하는기재를포함한다. 상기경피투과용약물전달시스템은약물방출효과가우수하며, 부작용이적어장기간사용할수 있다.
-
公开(公告)号：KR100265102B1
公开(公告)日：2000-09-01
申请号：KR1019980027384
申请日：1998-07-08
Applicant: 한국화학연구원
Abstract: 온도와 pH에 민감한 고분자로 구성된 나노미립구 및 그의 제조 방법에 관한 것이다. 이 제조 방법에 있어서, 알킬 아크릴아미드와 N,N-디메틸아미노에틸메타크릴레이트의 단량체를, 9:1∼7:3의 부피 비율로(7:3의 부피 비율은 포함되지 않음) 물과 친수성 유기 용매를 혼합한 혼합 용매에 용해하여 단량체 용액을 제조하고, 상기 단량체 용액에 반응 개시제를 첨가한다. 이 혼합물을 목적 생성물의 상전이 온도 이상에서 방치한 후, 얻어지는 생성물을 여과하고, 상기 여과물을 동결 건조한다. 이 방법은 간단한 공정으로 균일한 크기를 갖는 나노미립구를 제조할 수 있다.
-
公开(公告)号：KR1020000020874A
公开(公告)日：2000-04-15
申请号：KR1019980039665
申请日：1998-09-24
Applicant: 한국화학연구원
IPC: A61K9/70
CPC classification number: A61K9/7023 , A61K31/05 , A61K31/7048 , A61K47/32 , A61K47/34
Abstract: PURPOSE: A transdermal drug delivery system for treating and protecting dermal diseases is provided, which has high initial dermal permeation and is possible to store over an extended period and to reduce a period for forming a coating, and is easy to handle because of release of the coating of itself. Also, a process for producing the system is provided. CONSTITUTION: The process comprises the steps of adding a first water-soluble polymer to distilled water, adding a drug solution comprising solubilizing aids, covalent agent, polyethylene glycol, polyvinylpyrrolidone, drug and alcohol to the mixture followed by mixing the same to form a gel and adding a second water-soluble polymer to the gel.
Abstract translation: 目的：提供用于治疗和保护皮肤疾病的透皮药物递送系统，其具有高的初始皮肤渗透性，并且可以在延长的时间内存储并减少形成涂层的时间，并且易于处理，因为释放 本身的涂层。 此外，提供了一种用于生产该系统的过程。 方法：该方法包括以下步骤：向蒸馏水中加入第一种水溶性聚合物，向混合物中加入包含增溶助剂，共价试剂，聚乙二醇，聚乙烯吡咯烷酮，药物和醇的药物溶液，然后混合形成凝胶 并向凝胶中加入第二水溶性聚合物。
-
公开(公告)号：KR100178860B1
公开(公告)日：1999-03-20
申请号：KR1019960033056
申请日：1996-08-08
Applicant: 한국화학연구원
IPC: A61K9/107
Abstract: 고분자 및 단분자가 용해되어 있는 수용액과 기름을 혼합하여 o/w 에멀젼을 제조하고 이 에멀젼 용액에 약물과 기타 첨가물들을 혼합하고, 금속 이온 가교, UV를 이용한 가교 또는 냉각 등을 사용하여 혼합 용액을 고형화한 후 용도에 부합하는 형태로 성형한 에멀젼 네트웍을 이용한 국소 부위 약물 전달 체계는 치료 효과가 우수한 약물들을 안정한 형태로 보존하면서 약물을 조절적으로 방출할 수 있다.
-
公开(公告)号：KR1019970005280A
公开(公告)日：1997-02-19
申请号：KR1019950021742
申请日：1995-07-22
Applicant: 한국화학연구원
IPC: A61K9/70
Abstract: 생체적합성, 알레르기 비유발성의 고분자 물질을 극성 유기 용매에 용해시키고, 셀룰로우스 계통 또는 글라이콜 계통의 폴리 알콜 혹은 알콜화합물, 접착제 및 의약을 알칸올과 극성 유기 용매의 혼합 용매에 용해시킨 다음, 상기의 두 액상 물질을 균질화기로 완전히 균등한 혼합물이 되도록 혼합한 후, 상기 혼합 용액을 유리판 위에 일정한 두께로 도포한 다음, 건조하여 제조된 소수성 고분자 매트릭스를 이용하여 얻어지는 피부 약물전달 체계는 별도의 약물 저당 수단 및 접착제 코팅이 필요없으며, 약물 방출 조절이 우수한 피부 약물 전달 체계이다.
-
-
-
-
-
-
-
-
-
Search Results
53
records
(took 0.023 seconds)
